US · Healthcare · Biotechnology
EPS came in at -0.19 against a street estimate of -0.17 — a miss of 11.8%.
Analysts rate Corvus Pharmaceuticals Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $33.14.
| Fund | Stake |
|---|---|
| Orbimed Advisors LLC | 8.52% |
| BlackRock Inc | 7.32% |
| State Street Corp | 4.24% |
| Adams Street Partners LLC | 3.89% |
| Vanguard Capital Management, LLC | 3.85% |
| T. Rowe Price Associates, Inc. | 3.47% |
| Vivo Capital, LLC | 3.34% |
| Wellington Management Company LLP | 3.25% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 CORVUS PHARMACEUTICALS, INC. — FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash & Equivalents: $18.9 million (June 30, 202 | 2026-08-06 |
| Results announced · Q3 2026 CORVUS PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and marketable securities: $215.2 million as of June 30, | 2026-08-06 |
| Board / officer change · Q3 2026 CORVUS PHARMACEUTICALS, INC. – DOCUMENT SUMMARY OTHER NOTABLE POINTS • Ian T. Clark resigned from the company's board of directors effective July 22 | 2026-07-22 |
| Shareholder vote results · Q2 2026 CORVUS PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 11, 2026 • 84,090,424 shares outstanding as of record da | 2026-06-12 |
| Reg FD disclosure · Q2 2026 CORVUS PHARMACEUTICALS, INC. — FORM 8-K SUMMARY Report Date: May 14, 2026 --- HEADLINE NUMBERS • 72 patients enrolled in Phase 1 randomized, blinde | 2026-05-14 |
| Quarterly report · Q1 2026 CORVUS PHARMACEUTICALS, INC. – Q1 2026 SUMMARY HEADLINE NUMBERS • Cash and marketable securities: $236.7 million as of March 31, 2026 (up from $56.8 | 2026-05-07 |
| Proxy statement · Q2 2026 CORVUS PHARMACEUTICALS, INC. — PROXY SUMMARY FOR RETAIL INVESTORS --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two Class I Directors wit | 2026-04-24 |
| Annual report FY2025 CORVUS PHARMACEUTICALS, INC. – FORM 10-K SUMMARY HEADLINE NUMBERS • Company is a clinical-stage biopharmaceutical firm (not yet generating product r | 2026-03-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Corvus Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.